Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitor (ICI)-associated early cardiac adverse events (CAEs), mostly acute and fulminant myocarditis, have been well characterized and mainly occur during the first 90 days after ICI therapy initiation. ICI-associated late CAEs (occurring after the first 90 days of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolladille, Charles, Ederhy, Stephane, Allouche, Stéphane, Dupas, Querntin, Gervais, Radj, Madelaine, Jeannick, Sassier, Marion, Plane, Anne-Flore, Comoz, Francois, Cohen, Ariel Aron, Thuny, Franck Roland, Cautela, Jennifer, Alexandre, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057417/
https://www.ncbi.nlm.nih.gov/pubmed/31988143
http://dx.doi.org/10.1136/jitc-2019-000261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057417/
https://www.ncbi.nlm.nih.gov/pubmed/31988143
http://dx.doi.org/10.1136/jitc-2019-000261

Ejemplares similares